AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
AZD8848 Single Ascending Dose Study
- First Posted Date
- 2012-03-22
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 47
- Registration Number
- NCT01560234
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.
- First Posted Date
- 2012-03-21
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 17
- Registration Number
- NCT01559090
- Locations
- 🇯🇵
Research Site, Shinjuku-ku, Japan
Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of Formoterol
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 353
- Registration Number
- NCT01555099
- Locations
- 🇺🇦
Research Site, Zaporizhzhya, Ukraine
Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Children and Adolescent With Type 2 Diabetes
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 84
- Registration Number
- NCT01554618
- Locations
- 🇺🇦
Research Site, Odesa, Ukraine
Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France
- First Posted Date
- 2012-03-13
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT01552005
Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Aclidinium/formoterol 400/12μg
- First Posted Date
- 2012-03-13
- Last Posted Date
- 2017-02-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT01551888
- Locations
- 🇺🇸
Forest Investigative Site 001, Spartanburg, South Carolina, United States
An Observational Study of Statin Treatment Induced HDL Changes
Completed
- Conditions
- Cardiovascular Disease
- First Posted Date
- 2012-03-13
- Last Posted Date
- 2013-10-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120000
- Registration Number
- NCT01551784
A Study to Derive Normative Distribution of CIMT and to Determine Its Correlation With Cardiovascular Risk Factors
Completed
- Conditions
- Carotid Intima- Media Thickness
- First Posted Date
- 2012-03-13
- Last Posted Date
- 2013-07-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1200
- Registration Number
- NCT01551875
- Locations
- 🇮🇳
Research Site, Pune, India
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
Phase 2
Completed
- Conditions
- Mild Cognitive ImpairmentMild Alzheimer's Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 164
- Registration Number
- NCT01548287
- Locations
- 🇺🇸
Research Site, Salt Lake City, Utah, United States
Observe Real-life Allocation of Atypical Antipsychotics in the Acute Inpatient Management of Schizophrenia
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2012-03-06
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1076
- Registration Number
- NCT01544608
- Locations
- 🇦🇪
Research Site, Ras Al Khaimah, United Arab Emirates